Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients

Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients

<i>Background and Objectives</i>: Underpowered immune response to vaccines against SARS-CoV-2 was observed in solid organ transplant (SOT) recipients. A novel combination of monoclonal antibodies tixagevimab-cilgavimab (TGM/CGM) received authorization as pre-exposure prophylaxis (PrEP) i...

Full description

Bibliographic Details
Main Authors:	Roberta Angelico, Francesca Romano, Luigi Coppola, Marco Materazzo, Domiziana Pedini, Maria Sara Santicchia, Roberto Cacciola, Luca Toti, Loredana Sarmati, Giuseppe Tisone
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	Medicina
Subjects:	SARS-CoV-2 anti-SARS-CoV-2 antibodies’ titer COVID-19 disease pre-exposure prophylaxis long-active antibody tixagevimab
Online Access:	https://www.mdpi.com/1648-9144/59/12/2101

Similar Items

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
by: Anna Gidari, et al.
Published: (2024-02-01)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
by: Francesco Angotzi, et al.
Published: (2023-06-01)

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
by: Karolina Akinosoglou, et al.
Published: (2022-12-01)

Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
by: Saad Alhumaid, et al.
Published: (2022-12-01)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
by: Stefanie Dichtl, et al.
Published: (2022-09-01)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
by: David Totschnig, et al.
Published: (2022-10-01)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
by: Andrea Duminuco, et al.
Published: (2023-03-01)

SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience
by: Federica Pulvirenti, et al.
Published: (2023-10-01)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
by: Takahiro Shimizu, et al.
Published: (2023-03-01)

Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients
by: Cesare Ernesto Maria Gruber, et al.
Published: (2023-10-01)

Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2
by: Satoshi Kayukawa, et al.
Published: (2021-12-01)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
by: F. D. Richard Hobbs, et al.
Published: (2023-09-01)

Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19
by: Marina V. Zhuravleva, et al.
Published: (2023-02-01)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
by: Jinyoung Yang, et al.
Published: (2023-03-01)

Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chattogram Metropolitan Area, Bangladesh
by: Jahan Ara, et al.
Published: (2022-11-01)

Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients
by: Jowita Frączkiewicz, et al.
Published: (2024-03-01)

Development of Coronavirus Treatments Using Neutralizing Antibodies
by: Saman Fouladirad, et al.
Published: (2021-01-01)

Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies
by: Brandon J. Beddingfield, et al.
Published: (2021-11-01)

Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19
by: Joung Ha Park, et al.
Published: (2022-12-01)

Waning Humoral Response 6 Month after Double Vaccination with the mRNA-BNT162b2 Vaccine in Hemodialysis Patients
by: Vilma Balčiuvienė, et al.
Published: (2023-01-01)

Changes in spike protein antibody titer over 90 days after the second dose of SARS-CoV-2 vaccine in Japanese dialysis patients
by: Haruki Wakai, et al.
Published: (2022-11-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)

Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data
by: Yinong Young-Xu, et al.
Published: (2023-08-01)

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
by: Frank-Peter Tillmann, et al.
Published: (2021-10-01)

Machine learning analysis of humoral and cellular responses to SARS-CoV-2 infection in young adults
by: Ricards Marcinkevics, et al.
Published: (2023-05-01)

Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
by: Andrea Lombardi, et al.
Published: (2023-05-01)

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
by: Margherita Passariello, et al.
Published: (2023-06-01)

Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination
by: Marianne Graninger, et al.
Published: (2022-05-01)

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
by: Raul Pellini, et al.
Published: (2021-06-01)

Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan
by: Yen-Fang Huang, et al.
Published: (2023-06-01)

Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis
by: Mariem Gdoura, et al.
Published: (2022-07-01)

Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting
by: Emanuele Montomoli, et al.
Published: (2021-12-01)

The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19
by: Xuzhen Qin, et al.
Published: (2021-02-01)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-09-01)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
by: Thanyawee Puthanakit, et al.
Published: (2022-09-01)

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
by: Elaine C. Chen, et al.
Published: (2021-08-01)

Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2
by: Theocharis G. Konstantinidis, et al.
Published: (2021-06-01)

Evaluation of Natural and Vaccine-Induced Anti-SARS-CoV-2 Immunity: A Comparative Study between Different Groups of Volunteers
by: Maria Caterina Schipani, et al.
Published: (2022-04-01)

Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL)
by: Natalia Ruetalo, et al.
Published: (2021-11-01)

Neutralizing and enhancing antibodies against SARS-CoV-2
by: Yafei Liu, et al.
Published: (2022-12-01)